Neihulizumab is a monoclonal antibody against P-selectin glycoprotein ligand-1 (PSGL-1). Neihulizumab binds to human PSGL-1, thereby preferentially inducing apoptosis in late stage activated T cells. At sites of inflammation, the endothelium of blood vessels expresses P-selectin, and activated T cells bind to these sites and migrate through the expression of PSGL-1. In that manner, Neihulizumab is thought to target activated T cells and inhibit trafficking to sites of inflamed tissue[1].
References:
[1]. Sameem Abedin, et al. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. J Exp Pharmacol. 2020 Nov 26;12:549-557.
[2]. Sameem Abedin, et al. Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD). Blood (2022) 140 (Supplement 1): 10495-10497.